Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BNT 211

Next Previous
Search
Drug Profile

BNT 211

Alternative Names: Anti-claudin 6 CAR T-cell therapy - BioNTech; Anti-claudin 6 chimeric antigen receptor cell therapy - BioNTech; Anti-CLDN6 chimeric antigen receptor cell therapy - BioNTech; BNT-211; CLDN6 CAR-T therapy - BioNTech

Latest Information Update: 05 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 23 Apr 2025 BioNTech SE plans a phase II trial for Germ cell cancer (Second-line therapy or greater) in July 2025 (IV, Infusion) (NCT06940804)
  • 10 Mar 2025 BNT 211 receives Regenerative Medicine Advanced Therapy (RMAT) status for Solid tumours in USA
  • 13 Sep 2024 Efficacy and adverse events data from phase I/II clinical trials in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top